Product
Engineering Tumor Infiltrating Lymphocytes
1 clinical trial
5 indications
Indication
Solid TumorIndication
Gynecologic CancerIndication
Breast CancerIndication
Gastrointestinal CancerIndication
lung cancerClinical trial
A Phase I Study on Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-11-01